Abstract:Pharmacogenomic studies on psychiatric drugs have slowly identified genetic variations that influence drug metabolism and treatment effectiveness in patients with mental illness. However, most of these studies have predominantly centered on people of European descent, leaving a substantial knowledge gap on the clinical implications of current pharmacogenomic evidence in multi-ancestry populations such as Africans. Thus, whether pharmacogenomic (PGx) genetic testing implemented in European populations would be valid for a population of African origin is unknown. The objective of this review was to appraise previous psychiatric pharmacogenomic studies in Africa and highlight challenges and opportunities to initiate PGx testing in the region. A systematic literature search was conducted on PubMed, Scopus, and Web of Science to identify studies published in the English language up to January 26, 2024. The primary outcomes were treatment response, remission, side effects, and drug metabolism in African psychiatric patients. The review included 42 pharmacogenomic studies that explored the genetic profiles of psychiatric patients in Africa. Despite the limited number of studies, our review found strong evidence of pharmacogenomic diversity within the African populations, emphasizing the importance of pharmacogenomic research in this population. A high degree of variability and differences in the frequencies of cytochrome P450 (CYPs) genotypes have been reported within the African population. It is estimated that 28% of North Africans and Ethiopians are ultrarapid metabolizers of several medications, mainly attributed to the increased activity of the enzyme. This prevalence is significantly higher than that among Caucasians (10%), or Hispanics, Chinese, or Japanese populations (1%). Due to the defective allele (at a frequency of 14%) and allele (2% frequency), 5.2% of Ethiopians were identified as poor metabolizers of S-mephenytoin, a probe substrate used to assess the activity of the cytochrome P450 enzyme. In Tunisian patients with schizophrenia, genotyping the gene and using therapeutic drug monitoring (TDM) improved the effectiveness and safety of clozapine. Among South African patients with schizophrenia, antipsychotic treatment response was associated with two gene variants (rs13025959 in the gene with the ‘C’ allele and rs10380 in the gene with the ‘T’ allele). Overall, the review has identified evidence of pharmacogenomic diversity in African populations and recommended expanding pharmacogenomic studies while introducing PGx testing in this population. For the few characterized genes, Africans showed qualitative and quantitative differences in the profile of pharmacogenetic variants when compared to other ethnic groups. Limited research funding, inadequate infrastructure, and a shortage of skilled human resources might be a challenge, but by building upon local successes and through collaborations with international partners, it is possible to establish pharmacogenomic biobanks and leverage global genetic resources to initiate personalized treatment approaches in Africa.

Polymorphisms of ADME-related genes and their implications for drug safety and efficacy in Amazonian Amerindians

Increased Genetic Diversity of ADME Genes in African Americans Compared with Their Putative Ancestral Source Populations and Implications for Pharmacogenomics

The Extent and Impact of Variation in ADME Genes in Sub-Saharan African Populations

Distribution of CYP2D6 and CYP2C19 polymorphisms associated with poor metabolizer phenotype in five Amerindian groups and western Mestizos from Mexico

Pharmacogenomic implications of the differential distribution of CYP3A5 metabolic phenotypes among Latin American populations

NUDT15 and TPMT polymorphisms in three distinct native populations of the Brazilian Amazon

Genetic architectures of ADME genes in five Eurasian admixed populations and implications for drug safety and efficacy.

Differential distribution of NAT2 polymorphisms and NAT2 acetylator phenotypes among indigenous populations of the Brazilian Amazon

Afro-Latin American Pharmacogenetics of CYP2D6, CYP2C9, and CYP2C19 in Dominicans: A Study from the RIBEF-CEIBA Consortium

Ethnic differences in pharmacogenomic variants: a south Asian perspective

Host genetics and the profile of COVID-19 in indigenous people from the Brazilian Amazon: A pilot study with variants of the ACE1, ACE2 and TMPRSS2 genes

Genomic investigation on genes related to mercury metabolism in Amazonian indigenous populations

Molecular Profile of Important Genes for Radiogenomics in the Amazon Indigenous Population

Psychiatric Level 1A evidence pharmacogenomics in a Brazilian admixed cohort and global populations

Genetic variability among Mexican Mestizo and Amerindian populations based on three ABCB1 polymorphisms

Identification of adverse drug reactions that may be related to pharmacogenetics in a public hospital in the South of Brazil

Global Patterns of Genetic Diversity and Signals of Natural Selection for Human ADME Genes.

Ancestral diversity in pharmacogenomics affects treatment for Hispanic/Latine populations with inflammatory bowel disease

Molecular Basis of Ethnic Differences in Drug Disposition and Response

Assessing the Occurrence and Influence of Cancer Chemotherapy-Related Pharmacogenetic Alleles in the Chilean Population

Pharmacogenomic Diversity in Psychiatry: Challenges and Opportunities in Africa